Report for Knapp MJ

General

Full name :

First name :

Mail :

Zip Code :

City :

Country :

Email :

Phone :

Fax :

Website :

Directory :

References (8)

Title : Safety of tacrine: clinical trials, treatment IND, and postmarketing experience - Gracon_1998_Alzheimer.Dis.Assoc.Disord_12_93
Author(s) : Gracon SI , Knapp MJ , Berghoff WG , Pierce M , DeJong R , Lobbestael SJ , Symons J , Dombey SL , Luscombe FA , Kraemer D
Ref : Alzheimer Disease & Associated Disorders , 12 :93 , 1998
Abstract : Gracon_1998_Alzheimer.Dis.Assoc.Disord_12_93
ESTHER : Gracon_1998_Alzheimer.Dis.Assoc.Disord_12_93
PubMedSearch : Gracon_1998_Alzheimer.Dis.Assoc.Disord_12_93
PubMedID: 9651138

Title : Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease - Fontana_1998_Br.J.Clin.Pharmacol_46_221
Author(s) : Fontana RJ , deVries TM , Woolf TF , Knapp MJ , Brown AS , Kaminsky LS , Tang BK , Foster NL , Brown RR , Watkins PB
Ref : British Journal of Clinical Pharmacology , 46 :221 , 1998
Abstract : Fontana_1998_Br.J.Clin.Pharmacol_46_221
ESTHER : Fontana_1998_Br.J.Clin.Pharmacol_46_221
PubMedSearch : Fontana_1998_Br.J.Clin.Pharmacol_46_221
PubMedID: 9764962

Title : Long-term tacrine treatment in patients with Alzheimer's disease -
Author(s) : Solomon PR , Knapp MJ , Gracon SI , Groccia M , Pendlebury WW
Ref : Lancet , 348 :275 , 1996
PubMedID: 8684234

Title : The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity - Fontana_1996_Hepatology_23_1429
Author(s) : Fontana RJ , Turgeon DK , Woolf TF , Knapp MJ , Foster NL , Watkins PB
Ref : Hepatology , 23 :1429 , 1996
Abstract : Fontana_1996_Hepatology_23_1429
ESTHER : Fontana_1996_Hepatology_23_1429
PubMedSearch : Fontana_1996_Hepatology_23_1429
PubMedID: 8675160

Title : Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis - Green_1995_Br.J.Clin.Pharmacol_39_411
Author(s) : Green VJ , Pirmohamed M , Kitteringham NR , Knapp MJ , Park BK
Ref : British Journal of Clinical Pharmacology , 39 :411 , 1995
Abstract : Green_1995_Br.J.Clin.Pharmacol_39_411
ESTHER : Green_1995_Br.J.Clin.Pharmacol_39_411
PubMedSearch : Green_1995_Br.J.Clin.Pharmacol_39_411
PubMedID: 7640148

Title : Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease - Watkins_1994_JAMA_271_992
Author(s) : Watkins PB , Zimmerman HJ , Knapp MJ , Gracon SI , Lewis KW
Ref : Jama , 271 :992 , 1994
Abstract : Watkins_1994_JAMA_271_992
ESTHER : Watkins_1994_JAMA_271_992
PubMedSearch : Watkins_1994_JAMA_271_992
PubMedID: 8139084

Title : A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group - Knapp_1994_JAMA_271_985
Author(s) : Knapp MJ , Knopman DS , Solomon PR , Pendlebury WW , Davis CS , Gracon SI
Ref : Jama , 271 :985 , 1994
Abstract : Knapp_1994_JAMA_271_985
ESTHER : Knapp_1994_JAMA_271_985
PubMedSearch : Knapp_1994_JAMA_271_985
PubMedID: 8139083

Title : The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease - Knopman_1994_Neurology_44_2315
Author(s) : Knopman DS , Knapp MJ , Gracon SI , Davis CS
Ref : Neurology , 44 :2315 , 1994
Abstract : Knopman_1994_Neurology_44_2315
ESTHER : Knopman_1994_Neurology_44_2315
PubMedSearch : Knopman_1994_Neurology_44_2315
PubMedID: 7991118